These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32062877)

  • 21. Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.
    Passiglia F; Commendatore O; Vitali M; Conca R
    Future Oncol; 2018 Jun; 14(13s):41-60. PubMed ID: 29989452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent clinical trials of immunotherapy in non-small-cell lung cancer.
    Gkolfinopoulos S; Mountzios G
    Immunotherapy; 2019 Apr; 11(6):461-466. PubMed ID: 30860438
    [No Abstract]   [Full Text] [Related]  

  • 24. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
    Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy.
    Takamori S; Takada K; Shimokawa M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Takenoyama M; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
    Int J Cancer; 2020 Oct; 147(8):2327-2334. PubMed ID: 32356560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer.
    Pirker R
    Curr Opin Oncol; 2019 Jan; 31(1):24-28. PubMed ID: 30418192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring immunotherapy outcomes with circulating tumor DNA.
    Goldberg SB; Patel AA
    Immunotherapy; 2018 Sep; 10(12):1023-1025. PubMed ID: 30185140
    [No Abstract]   [Full Text] [Related]  

  • 28. Emerging biomarkers for immune checkpoint inhibition in lung cancer.
    Cyriac G; Gandhi L
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):269-277. PubMed ID: 29782924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Principles of Immunotherapy in Non-Small Cell Lung Cancer.
    Hsu ML; Naidoo J
    Thorac Surg Clin; 2020 May; 30(2):187-198. PubMed ID: 32327177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity.
    Rossi S; Castello A; Toschi L; Lopci E
    Immunotherapy; 2018 Jul; 10(9):797-805. PubMed ID: 30008262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
    Memon H; Patel BM
    Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns.
    Brassart-Pasco S; Dalstein V; Brassart B; Dewolf M; Clavel C; Oudart JB
    Pharmacogenomics; 2020 Jul; 21(10):705-720. PubMed ID: 32567537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
    Lim SW; Ahn MJ
    Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
    Rassy E; Mezquita L; Remon J; Besse B
    Immunotherapy; 2019 Sep; 11(13):1149-1160. PubMed ID: 31361172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
    Pabani A; Butts CA
    Curr Oncol; 2018 Jun; 25(Suppl 1):S94-S102. PubMed ID: 29910652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
    Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
    J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.
    Martinez P; Peters S; Stammers T; Soria JC
    Clin Cancer Res; 2019 May; 25(9):2691-2698. PubMed ID: 30642913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.